Evidence map›Paper›PMID 34839177›Full record

ArticleCytokine2022

Partial STAT5 signaling is sufficient for CD4

Michelle Fleury, Cristina Vazquez-Mateo, Jaileene Hernandez-Escalante, Hans Dooms

Open access · greenAbstract read
In one paragraph

Article in Cytokine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. CD4Frontiers in immunology · 2023
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Michelle FleuryArthritis and Autoimmune Diseases Research Center, Rheumatology Section, Department of Medicine, Boston University School of Medicine, Boston MA 02118, United States; Department of Microbiology, Boston University School of Medicine, Boston MA 02118, United States.
Cristina Vazquez-MateoArthritis and Autoimmune Diseases Research Center, Rheumatology Section, Department of Medicine, Boston University School of Medicine, Boston MA 02118, United States.
Jaileene Hernandez-EscalanteArthritis and Autoimmune Diseases Research Center, Rheumatology Section, Department of Medicine, Boston University School of Medicine, Boston MA 02118, United States; Department of Microbiology, Boston University School of Medicine, Boston MA 02118, United States.
Hans DoomsArthritis and Autoimmune Diseases Research Center, Rheumatology Section, Department of Medicine, Boston University School of Medicine, Boston MA 02118, United States; Department of Microbiology, Boston University School of Medicine, Boston MA 02118, United States; Department of Pathology, University of California San Francisco, San Francisco CA 94143, United States. Electronic address: hdooms@bu.edu.
Boston University · USUniversity of California, San Francisco · US

Funding

RESEARCH TRAINING IN IMMUNOLOGYT32AI007309 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GUMMULURU, SURYARAM · 1988 to 2024
$7.4M
MECHANISMS UNDERLYING THE ROLE OF INTERLEUKIN-7 IN TYPE 1 DIABETESR01DK102911 · NIDDK · BOSTON UNIVERSITY MEDICAL CAMPUS · PI DOOMS, HANS PETER · 2016 to 2020
$2.0M
NIAID NIH HHS T32 AI007309NIDDK NIH HHS R01 DK102911
6 · The paper itself

Abstract

Signal transducer and activator of transcription 5 (STAT5) plays an important role in regulating gene expression in response to cytokines of the common (γc) chain family. In this capacity, STAT5 promotes CD8

Indexed as

Immunologic MemorySTAT5 Transcription FactorCD4-Positive T-LymphocytesLymphocyte ActivationSignal TransductionSTAT5 Transcription Factor

Identifiers

PMID34839177
PMCPMC8761165
OpenAlexW3216606406

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.